VVUS Related Trader Talk
-
Arena (ARNA) Clears Final BELVIQ Marketing Hurdle; Could Make U.S. Debut in June
-
VIVUS (VVUS) Qsymia Growth Seen at 55% in Q1 from Q4
-
VIVUS (VVUS) March Qsymia Shipments Rose 29%
-
VIVUS, Inc. (VVUS) Positive; Shorts Cover Into REMS Modification for Qsymia
-
VIVUS (VVUS) Qsymia Prescriptions Fall for Second Week; Promotion Still Ongoing
-
Vivus (VVUS) Financing Agreement Does Not Appear Cheap - Analyst
-
VIVUS (VVUS) Enters $110M non-Equity Financing Agreement; Will Draw $50M Initially
-
Arena (ARNA), VIVUS (VVUS) Face Uphill Obesity Battle as Costs Play Key Role
-
VIVUS (VVUS) Cuts Qsymia Price by About 70%; Arena (ARNA) on Watch
-
Arena (ARNA) Short Interest Still High into Q4 Results
-
Arena (ARNA) Will Need Lower Co-Payments, Broader Coverage for Belviq Success (VVUS)
-
Stocks Crossing 50-Day SMA 02/05: (JCP) (VVUS) (TER) Above; (NIHD) (EW) (TE) Below
-
VIVUS (VVUS) Peers Tick Higher Amid Positive Qsymia Data (ARNA) (OREX)
-
Shorts Target VIVUS (VVUS) Following January Pop; May be Entering 'Oversold' Territory
-
First Manhattan Raises Stake in VIVUS (VVUS) to 7.23%; Has Discussions with Management
-
Vivus (VVUS) Spikes on Partnership Discussions
-
VIVUS (VVUS) Qsymia Prescriptions Jump 140%+ After Free Trial Program Starts
-
Stocks Crossing 50-Day SMA 01/02: (KO) (JCP) (BRCD) Above; (EMC) (VVUS) (M) Below
-
Stocks Crossing 50-Day SMA 12/31: (HPQ) (ZNGA) (MCP) Above; (PFE) (VVUS) (WPI) Below
-
Stocks Crossing 50-Day SMA 12/28: (MHR) (GGB) (YONG) Above; (VVUS) (SD) (AUQ) Below
-
Stocks Crossing 50-Day SMA 12/20: (WFT) (LLY) (DHI) Above; (SD) (VVUS) (DECK) Below
-
Arena (ARNA), Orexigen (OREX) on Watch as Major PBM Adds Qsymia to Formularies List (VVUS)
-
Orexigen (OREX) Slumps as Many Expected 'Better News' for Contrave
-
Vivus (VVUS) Surges as Qsymia Prescriptions Rise 46%
-
Stocks Crossing 50-Day SMA 12/10: (HPQ) (MCP) (ACI) Above; (AIG) (SIRI) (SWHC) Below
-
VIVUS (VVUS) Surges Higher on Aetna Bulletin (ARNA)
-
QVT Financial Lowers Stake in Vivus, Inc. (VVUS) to 8.3%; Says Company Should Be Sold
-
VIVUS (VVUS) Ticks Lower; Wider Q3 Loss Attributed to Qsymia Launch, Expansion (ARNA) (OREX)
-
Latest Qsymia Data Shapes Up Potential Bear Case for VIVUS (VVUS) and Peers (ARNA) (OREX)
-
Obesity Pill Pharma Gear Up to Report Q3 Results Next Week (ARNA) (OREX) (VVUS)
-
Wells Outlines Paths for VIVUS (VVUS) Following CHMP Denial of Qsiva Marketing App
-
Arena (ARNA), Orexigen (OREX) on Watch after CHMP Denies VIVUS (VVUS) Qsiva in EU
-
Arena (ARNA) Runs Higher as VIVUS (VVUS) Seeks Broader Obesity Pill Distribution
-
FDA Might Allow for Faster Approval of Obesity Drugs (VVUS) (ARNA) (OREX)
-
Stocks Crossing 50-Day SMA 10/10: (S) (VVUS) (SHO) Above; (CVX) (VLO) (GRPN) Below
-
VIVUS (VVUS) Higher as Qsymia Prescriptions Show Confident Growth
-
VIVUS' (VVUS) Qsymia Prescription Insurer Pay Rate Rose 5% in Week Two
-
Large VIVUS (VVUS) Call Block Crosses Above Bid
-
Stocks Crossing 50-Day SMA 09/24: (KWK) (NVE) (RSH) Above; (ARNA) (ATML) (ALU) Below
-
VIVUS (VVUS) Gets Jump on Arena (ARNA); Quietly Discloses Qsymia Availability in U.S.
-
Arena Pharmaceuticals (ARNA) Sees Upside
-
VIVUS (VVUS), Arena (ARNA) Tick Higher on Positive Orexigen (OREX) News
-
Obesity Drug Makers Gears Up for Busy Sept. Conference Schedule (ARNA) (OREX) (VVUS)
-
Arena (ARNA), Orexigen (OREX) Lift With VIVUS (VVUS)
-
UPDATE: VIVUS (VVUS) Pops Higher Early on Volume; Insider Boosts Stake 12.5%
-
VIVUS (VVUS) Volatile as Qsymia Posted in FDA Orange Book
-
Large VIVUS, Inc. (VVUS) Holder Gets Bullish, Takes Stake Back Above 5% Level
-
Arena (ARNA) Higher as VIVUS (VVUS) Downgrade is Company-Specific, Not Industry Issue
-
VIVUS (VVUS) Peers Pressured as Analyst Takes Cautious Stance on Obesity Drug (ARNA) (OREX)
-
Arena Pharmaceuticals (ARNA) Jumps on Takeover Speculation
Back to VVUS Stock Lookup
